This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Celldex' CDX-0159 Urticaria Phase 1b Data presented at EAACI 2021

Ticker(s): CLDX

Who's the expert?

Institution: Charité Universitätsmedizin in Berlin

  • Professor of Dermatology and Allergy and Director of Research at the Department of Dermatology and Allergy, Allergie-Centrum-Charité of the Charité - Universitätsmedizin in Berlin.
  • Coordinator of the GA²LEN urticaria centers of reference and excellence (UCARE) network & Coordinator of the National Priority Programme “Physiological functions of mast cells”. 
  • Has published >557 publications in peer-review journals and 40 books and book chapters.

Interview Questions

Roughly how many patients with urticaria do you currently manage?

Added By: c_admin

What were your thoughts on the Phase 1B data for CDX-0159?

Added By: c_admin

Differences between CSU and chronic inducible urticaria?

Added By: user18544032

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.